Quarterly ResultMay 8, 2026, 04:17 PM
Entera Bio Q1 Net Loss $3.5M; Secures $10M Private Placement
AI Summary
Entera Bio Ltd. reported a net loss of $3.5 million for the first quarter of 2026, an increase from $2.6 million in the prior year. The company's cash and cash equivalents decreased to $4.1 million by March 31, 2026, and management noted substantial doubt about its ability to continue as a going concern. However, in April 2026, Entera Bio completed a private placement, raising approximately $10.0 million to support its operations and the planned Phase 3 study for EB613. Additionally, the collaboration agreement with OPKO was expanded to include the development of EB612 for hypoparathyroidism.
Key Highlights
- Q1 2026 net loss increased to $3.5 million from $2.6 million in Q1 2025.
- Cash and cash equivalents were $4.1 million as of March 31, 2026, down from $7.1 million.
- Net cash used in operating activities increased to $3.1 million in Q1 2026.
- Company raised $10.0 million gross proceeds from a private placement in April 2026.
- Collaboration with OPKO expanded in February 2026 to include EB612 for hypoparathyroidism.
- Research and development expenses rose to $2.3 million in Q1 2026 from $1.1 million.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
Price Impact
More from ENTX